Skip to main content

Kewalramani Reshma's Form 4 filing

Vertex Pharmaceuticals Inc (VRTX) · filed May 1, 2023

Accession no.
0001209191-23-026270
Filed
May 1, 2023
Trade date
Apr 27, 2023
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions. Open-market sales total $1.12M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kewalramani ReshmaCIK 0001735944Director, Officer (CEO & President)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 27, 2023Common StockSSaleDisposed−1,611$338.69F2,F3−$545,629.59128,358Direct
Apr 27, 2023Common StockSSaleDisposed−1,668$339.43F2,F4−$566,169.24126,690Direct
Apr 27, 2023Common StockSSaleDisposed−38$340.19−$12,927.22126,652Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Referenced by the price of 2 transactions in Table I.

F3

Open market sales reported on this line occurred at a weighted average price of $338.69 (range $338.00 to $338.99).

Referenced by the price of 1 transaction in Table I.

F4

Open market sales reported on this line occurred at a weighted average price of $339.43 (range $339.00 to $339.98).

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)